bupropion hydrochloride tablet extended release
1 INDICATIONS AND USAGE Bupropion hydrochloride extended-release tablets (SR) are indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM ) . The efficacy of bupropion in the treatment of a major depressive episode was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult subjects with MDD [see Clinical Studies ( 14 )]. The efficacy of bupropion hydrochloride extended-release tablets (SR) in maintaining an antidepressant response for up to 44 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial [see Clinical Studies ( 14 )] . • Bupropion hydrochloride extended-release tablets (SR) are an aminoketone antidepressant, indicated for the treatment of major depressive disorder (MDD). ( 1 )
eon labs, inc.
ROUND BLUE E 410
E 410 ROUND BLUE
Related Pills
bupropion hydrochloride 200 mg
eon labs, inc.
bupropion hydrochloride tablet extended release
eon labs, inc.
bupropion hydrochloride tablet extended release
eon labs, inc.
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
16 HOW SUPPLIED/STORAGE AND HANDLING
BUPROPION HYDROCHLORIDE extended-release tablets, USP (SR), for oral administration, are available as 100 mg aquamarine, round, biconvex, film-coated tablets, debossed “ E ” over “410” on one side and plain on the other side and supplied as: NDC 0185-0410-60 bottles of 60 NDC 0185-0410-01 bottles of 100 NDC 0185-0410-52 bottles of 250 NDC 0185-0410-05 bottles of 500 150 mg Plum, round, biconvex, film-coated tablets, debossed “ E ” over “415” on one side and plain on the other side and supplied as: NDC 0185-0415-60 bottles of 60 NDC 0185-0415-01 bottles of 100 NDC 0185-0415-52 bottles of 250 NDC 0185-0415-05 bottles of 500 200 mg Light pink, round, biconvex, film-coated tablets, debossed “ E ” on one side and debossed “1111” on the other side and supplied as: NDC 0185-1111-60 bottles of 60 NDC 0185-1111-01 bottles of 100 NDC 0185-1111-52 bottles of 250 NDC 0185-1111-05 bottles of 500 NDC 0185-1111-10 bottles of 1000 Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Dispense contents in a tight, light-resistant container as defined in the USP with a child-resistant closure, as required. Protect from light and moisture. Keep tightly closed. KEEP OUT OF THE REACH OF CHILDREN.
More pills like ROUND E 410